EVEROLIMUS MSDS PDF

Overview Everolimus is a derivative of Rapamycin sirolimus , and works similarly to Rapamycin as an mTOR mammalian target of rapamycin inhibitor[]. It is currently used as an immunosuppressant to prevent rejection of organ transplants. Everolimus is indicated for the treatment of numerous diseases and disorders. It is the protein kinase at the core of this intricate and continually evolving pathway, controls cellular growth and behavior, impacting vital processes from immune reactivity to cancer progression[17, 18]. This inhibition reduces the activity of effectors downstream, which leads to a blockage in the progression of cells from G1 into S phase, and subsequently inducing cell growth arrest and apoptosis. Everolimus also inhibits the expression of hypoxia-inducible factor, leading to a decrease in the expression of vascular endothelial growth factor[19, 20].

Author:Mogami Dazahn
Country:Timor Leste
Language:English (Spanish)
Genre:Video
Published (Last):11 June 2005
Pages:365
PDF File Size:19.65 Mb
ePub File Size:20.52 Mb
ISBN:212-2-92775-290-7
Downloads:91832
Price:Free* [*Free Regsitration Required]
Uploader:Voodookora



Overview Everolimus is a derivative of Rapamycin sirolimus , and works similarly to Rapamycin as an mTOR mammalian target of rapamycin inhibitor[]. It is currently used as an immunosuppressant to prevent rejection of organ transplants. Everolimus is indicated for the treatment of numerous diseases and disorders. It is the protein kinase at the core of this intricate and continually evolving pathway, controls cellular growth and behavior, impacting vital processes from immune reactivity to cancer progression[17, 18].

This inhibition reduces the activity of effectors downstream, which leads to a blockage in the progression of cells from G1 into S phase, and subsequently inducing cell growth arrest and apoptosis. Everolimus also inhibits the expression of hypoxia-inducible factor, leading to a decrease in the expression of vascular endothelial growth factor[19, 20].

The result of everolimus inhibition of mTOR is a reduction in cell proliferation, angiogenesis, and glucose uptake. Pharmacokinetics Oral everolimus is absorbed rapidly, and reaches peak concentration after 1.

Steady state is reached within 7 days, and steady-state peak and trough concentrations, and area under the concentration-time curve AUC , are proportional to dosage. In adults, everolimus pharmacokinetic characteristics do not differ according to age, weight or sex, but bodyweight-adjusted dosages are necessary in children.

Adverse reactions Some serious adverse reactions associated with Everolimus include non-infection pneumonitis, infections, severe hypersensitivity reactions, angioedema with concomitant use of ACE inhibitors, stomatitis, renal failure, impaired wound healing, metabolic disorders and myelosuppression[10].

Various common side effects include Bloating or swelling of the face, arms, hands, lower legs, or fee bloody nose, chest pain or tightness, chills, cough, decreased weight, diarrhea, difficult or labored breathing, difficulty with swallowing, fever, general feeling of discomfort or illness, hoarseness, lower back or side pain, painful or difficult urination, rapid weight gain, sores, ulcers, or white spots on the lips, tongue, or inside the mouth and tingling of the hands or feet[23].

Less common side effects include bleeding gums, bloody urine, blurred vision, burning, crawling, itching, numbness, prickling, or tingling feelings, coughing up blood, extreme tiredness or weakness, fast, pounding, or irregular heartbeat or pulse, increased thirst or urination, irregular breathing, loss of appetite, nausea, nervousness, nosebleeds, prolonged bleeding from cuts, red or black, tarry stools, red or dark brown urine, slow heartbeat, stomach ache, sweating, unusual tiredness or weakness and vomiting[23].

Warning and precautions People who are allergic to Everolimus should be disabled. Since it can increase your risk of serious infections or getting certain cancers, such as lymphoma or skin cancer. The patients should ask their doctor about the specific risk[10, 23]. Patients who have the following conditions should consult for doctor for advice before administration: problem in digesting lactose or galactose sugar ; high cholesterol or triglycerides; liver disease; a heart transplantation; or skin cancer in them or their family members[23].

Since it may harm the unborn baby as well as affect fertility the capability to have children , women should take effective birth control during administration of Everolimus and for at least eight weeks after stopping drugs. Should consult the doctor for advice if you want to or has become pregnant. It may also affect the fertility of men as well.

It is generally not recommended to have breast-feed during the administration of Everolimus for women[10, 23].

BRUCHUS RUFIMANUS PDF

Everolimus Tablets (Zortress)

Warning This medicine may raise the chance of very bad and sometimes deadly infections. Talk with the doctor. This medicine may raise the chance of getting cancer like lymphoma or skin cancer. Call your doctor right away if you have a change in color or size of a mole, a skin lump or growth, a big weight loss, night sweats, or swollen glands. In people who have had a kidney transplant, the risk of a blood clot in your kidney transplant may be raised. This may lead to loss of the kidney.

EL CANTAR DE LOS NIBELUNGOS EDITORIAL PORRUA PDF

Everolimus

.

HOW TO CONVERT RTFD TO PDF

.

Related Articles